LKL INTERNATIONAL BERHAD
Wisma LKL, No. 3, Jalan BS 7/18,
Kawasan Perindustrian Bukit Serdang,
Seksyen 7, 43300 Seri Kembangan,
Selangor Darul Ehsan, Malaysia.
KUALA LUMPUR: LKL International Bhd is upbeat on its financial year ending September 30, 2022 (FY22) driven by healthy orders for medical/healthcare beds and accessories, as well as upcoming launch of its lifestyle pharmacy venture.
LKL International said it was also targeting to commence its first innovative lifestyle pharmacy chain outlet in the fourth quarter of this year. Executive director Lim Ming Chang said the company intended to serve not just healthcare providers with its medical beds and peripherals, but also the general public by entering the business-to-consumer (B2C) space through its new lifestyle pharmacy chain. “Therefore, apart from our manufacturing and trading segments, our latest pharmacy retail chain space will allow us to capitalise on consumers’ increasingly health-conscious stance amidst the pandemic,” Lim said in a statement.
LKL International registered a net loss of RM1.9 million in the fifth quarter (Q5) ended July 31, 2021 due to expenses for employees’ share option scheme. The company delivered revenue of RM13.5 million in Q5.
Revenue from the manufacturing division, including the manufacturing of medical beds as well as medical peripherals and accessories, made up RM8.6 million or 63.9 per cent of total company’s revenue.
Meanwhile, revenue from the trading division, including trading of medical peripherals and accessories as well as medical devices, made up RM4.9 million or 36.1 per cent of total company’s revenue. Geographically, local sales constituted RM12.5 million or 92.8 per cent of total company’s revenue.
Exports constituted RM0.97 million or 7.2 per cent of the company’s revenue in Q5 2021, with RM0.96 million or 7.1 per cent from Asia and RM0.02 million or 0.1 per cent from Middle East.
For the 15-month period, the company posted revenue of RM63.4 million and net loss of RM5.7 million. Due to the change in financial year end, there are no comparative figures provided in the financial report.